Table 3 Review of the literature and comparison of outcomes based on HPV status in OPSCC treated with radiotherapy with or without concurrent chemotherapy.
From: Long-term outcomes of consecutive patients of oropharyngeal cancer treated with radical radiotherapy
Author/Journal/ Year | Details | Time in year | HPV-Positive | HPV-Negative | ||||
|---|---|---|---|---|---|---|---|---|
LC (%) | DFS (%) | OS (%) | LC (%) | DFS (%) | OS (%) | |||
Fakhry C/ JNCI/ 2008 [22] | N 52 Multi institution M/Fup 39mo | 2 | N.A. | 86 | 95 | N.A. | 53 | 62 |
Gillison M/ JCO/2012 [23] | N 190 Multi institution M/Fup 9.3 yr | 5 | N.A. | 44 | 49 | N.A. | 19 | 20 |
Ang K/ NEJM/ 2010 [14] | N 323 Multi Institution M/Fup 4.8 yr | 3 | N.A. | 74 | 82 | N.A. | 43 | 57 |
P. Lassen/ RO/ 2011 [24] | N 200 Multi Institution M/Fup N.A. | 5 | 69 | N.A. | 62 | 57 | N.A. | 47 |
Posner/ Annal of oncology/2011 [25] | N 111 Multi Institution M/Fup 83mo surviving patients | 5 | N.A. | 78 | 82 | N.A. | 28 | 35 |
B O’Sullivan/ Lancet/ 2016 [11] | N 2603 Multi Institution M/Fup N.A. | 5 | N.A. | N.A. | 80 | N.A. | N.A. | 48 |
P. Lassen/ RO/ 2018 [7] | N 815 Multi Institution M/Fup N.A. | 5 | N.A. | 55 | 60 | N.A. | 24 | 27 |
A Hogmo/Acta Oncologica/ 2022 [8] | N 414 Multi Institution M/Fup N.A. | 5 | N.A. | 73 | 77 | N.A. | N.A. | 38 |
P Lassen/ RO/2023 [9] | N 8595 Multi Institution M/Fup N.A. | 5 | N.A. | N.A. | 76 | N.A. | N.A. | 34 |
Present Study | N 630 Single Institution M/Fup 21mo | 3 5 | 87 84 | 72 64 | 76 69 | 47 44 | 31 26 | 39 32 |
